SanBio Company Limited (OTCMKTS:SNBIF) Sees Significant Decrease in Short Interest

SanBio Company Limited (OTCMKTS:SNBIF) saw a significant drop in short interest in August. As of August 31st, there was short interest totalling 545,300 shares, a drop of 29.8% from the August 15th total of 776,900 shares. Based on an average trading volume of 2,400 shares, the short-interest ratio is currently 227.2 days.

SanBio Price Performance

SNBIF remained flat at C$3.85 during trading on Monday. SanBio has a twelve month low of C$3.80 and a twelve month high of C$4.25. The firm has a 50 day moving average price of C$3.85 and a 200 day moving average price of C$3.84.

SanBio Company Profile

SanBio Company Limited develops, produces, and sells regenerative cell medicines for the central nervous system. The company develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan. Its research pipeline products also comprise SB623 for ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigments, Parkinson's disease, spinal cord injury, and Alzheimer's disease; SB618 for peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis.